Form 8-K - Current report:
SEC Accession No. 0001213900-24-100231
Filing Date
2024-11-19
Accepted
2024-11-19 17:10:08
Documents
15
Period of Report
2024-11-19
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0221824-8k_emma.htm   iXBRL 8-K 27074
2 NOVEMBER 19, 2024 PRESS RELEASE ea022182401ex99-1_emma.htm EX-99.1 46407
3 GRAPHIC ex99-1_001.jpg GRAPHIC 3635
  Complete submission text file 0001213900-24-100231.txt   255459

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE emma-20241119.xsd EX-101.SCH 3030
5 XBRL LABEL FILE emma-20241119_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE emma-20241119_pre.xml EX-101.PRE 22369
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0221824-8k_emma_htm.xml XML 3359
Mailing Address 21250 HAWTHORNE BOULEVARD, SUITE 800 TORRANCE CA 90503
Business Address 21250 HAWTHORNE BOULEVARD, SUITE 800 TORRANCE CA 90503 310-214-0065
Emmaus Life Sciences, Inc. (Filer) CIK: 0000822370 (see all company filings)

EIN.: 870419387 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35527 | Film No.: 241477210
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)